stem cells are set to take root in the Indian drug market. They will be launched as a constituent of umbilical cord blood (ucb) to help treat fatal diseases such as thalassemia, anaemia and leukaemia. Reliance Life Sciences (rls), a subsidiary of the Reliance group of Industries, has become the first Indian company to be given permission to market the ucb.
To be called
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/news/blood-infuses-new-hope
[2] http://admin.indiaenvironmentportal.org.in/category/newspaper/down-earth
[3] http://admin.indiaenvironmentportal.org.in/category/thesaurus/trade
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drug-industry
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/anaemia
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/technology
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/india
